Clinical Trial Detail

NCT ID NCT03052608
Title A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Pfizer
Indications

lung non-small cell carcinoma

Therapies

Lorlatinib

Crizotinib

Age Groups: adult senior

Additional content available in CKB BOOST